GH (Guardant Health) YoY EBITDA Growth: -14.67% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GH Guardant Health Inc GH
65 GF Score
Price $179.46
GF Value $66.66
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Guardant Health YoY EBITDA Growth?

Guardant Health GH -2.04% 65 YoY EBITDA Growth is -14.67% as of Jun. 2026. GuruFocus rates GH with a GF Score™ of 65/100 and a GF Value™ of $66.66 (Significantly Overvalued). The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Guardant Health's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -14.67%.

Guardant Health's EBITDA per Share for the three months ended in Jun. 2026 was $-0.82.

Guardant Health YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Guardant Health's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guardant Health YoY EBITDA Growth Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.81 -69.52 35.71 17.86 6.17

Guardant Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.76 15.94 -15.34 -13.59 -14.67
GH
65GF Score
Guardant Health Inc GH
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guardant Health YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Guardant Health's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-2.982--3.178)/ | -3.178 |
=6.17 %

Guardant Health's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.821--0.716)/ | -0.716 |
=-14.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -14.67% mean?
Guardant Health (GH) has a YoY EBITDA Growth of -14.67% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Guardant Health and its competitors.
Is Guardant Health's YoY EBITDA Growth too high?
Guardant Health's current YoY EBITDA Growth is -14.67%. Overall, Guardant Health has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's YoY EBITDA Growth compare to MEDP and DGX?
Guardant Health's YoY EBITDA Growth of -14.67% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Diagnostics & Research company?
A good YoY EBITDA Growth depends on the Medical Diagnostics & Research industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Guardant Health and its competitors. Guardant Health's current YoY EBITDA Growth is -14.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (GH) is currently considered Significantly Overvalued. The stock's GF Value™ is $66.66, compared to a current price of $179.46 — trading 169.2% above its estimated fair value. The current YoY EBITDA Growth is -14.67%. Guardant Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Guardant Health (GH), the current YoY EBITDA Growth is -14.67% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guardant Health (GH) Overvalued in 2026?

Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued. The current stock price of $179.46 is trading 169.2% above its estimated GF Value™ of $66.66. GuruFocus considers Guardant Health to be Significantly Overvalued.

Key valuation signals for GH:

  • YoY EBITDA Growth: -14.67%
  • GF Value™: $66.66 vs. price of $179.46 (169.2% above fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guardant Health Business Description

Other Exchanges 1GH:Italy5GH:Germany
Address 3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
65GF Score

Get the complete analysis for GH

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$179.46
Price
$66.66
GF Value